|

Avapritinib Clinical Trials

8 actively recruiting trials across 2 locations

Also known as: (S)-1-(4-fluorophenyl)-1-(2-(4-(6-(1-methyl-1Hpyrazol-4-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl)piperazin-yl)pyrimidin-5-yl)ethan-1-amine, AYVAKIT, AYVAKIT®, Ayvakit, Ayvakyt +4 more

Pipeline

Phase 1: 1Phase 2: 4Phase 4: 1

Top Sponsors

  • Children's Hospital of Soochow University2
  • Blueprint Medicines Corporation2
  • M.D. Anderson Cancer Center1
  • Institute of Hematology & Blood Diseases Hospital, China1
  • H. Lee Moffitt Cancer Center and Research Institute1

Indications

  • Cancer8
  • AML, Childhood2
  • Systemic Mastocytosis With an Associated Hematologic Neoplasm1
  • Mastocytosis, Systemic1
  • Indolent Systemic Mastocytosis1

Other6 trials

A Non-Interventional Study in Participants With Indolent Systemic Mastocytosis (ISM) in Germany
A Study Evaluating the Activity of Anti-cancer Treatments Targeting Tumor Molecular Alterations/Characteristics in Advanced / Metastatic Tumors.
Phase 2
Avapritinib Rollover Study
Phase 4
Clinical Study of Induction Therapy Options Based on Molecular Subtyping and MRD in Children and Adolescents With AML
Phase 2
MRD-positive AML Clinical Study
N/A
Safety and Efficacy of Avapritinib in Relapsed or Refractory Pediatric CBF-AML With KIT Mutation
Phase 2

Phoenix, Arizona1 trial

Avapritinib With Decitabine in Patients With SM-AHN

Mayo Clinic - Arizona

Phase 1

Houston, Texas1 trial

Avapritinib for the Treatment of CKIT or PDGFRA Mutation-Positive Locally Advanced or Metastatic Malignant Solid Tumors

M D Anderson Cancer Center

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.